IUSM Alzheimer's Disease Drug Discovery Center

IUSM 阿尔茨海默病药物研发中心

• 批准号: 10250434
• 负责人: Bruce T Lamb
• 金额: $ 745.29万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10250434
• 关键词: Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease model; Amyloid beta-Protein; Animal Disease Models; Basic Science; Biological Markers; Biology; Brain; Cause of Death; Clinical Research; Clinical Sciences; Clinical Trials Design; Communities; Custom; Data; Dimensions; Disease; Drug Targeting; Elements; Ensure; Feasibility Studies; Foundations; Generations; Genetic; Goals; Human Pathology; Immunization; Indiana; Institutes; Intervention; Investments; Lead; Methods; Mission; Modality; Modeling; Molecular; Nerve Degeneration; Neuroimmune; Pathway interactions; Patients; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Postdoctoral Fellow; Presenile Alzheimer Dementia; Probability; Process; Research; Research Personnel; Resources; Risk; Science; Scientist; Technology; Testing; Therapeutic; Time; Toxicology; Translating; Translational Research; United States; United States National Institutes of Health; Universities; Validation; Work; abeta accumulation; base; beta secretase; data access; data sharing; design; disability; drug candidate; drug development; drug discovery; experimental study; flexibility; gamma secretase; human disease; inhibitor/antagonist; innovation; insight; medical schools; novel; open data; physical property; pre-clinical; sharing platform; success; translational study; validation studies

The strategic goal of the Indiana University School of Medicine Alzheimer’s Disease Drug Discovery (ADDD) Center is to integrate sophisticated capability for early drug discovery and contribute to a broader study of emerging Alzheimer’s disease (AD) target hypotheses (beyond Ab) with the goal of generating new classes of potential therapeutics. Specifically, the ADDD CENTER will establish itself as a strategic and operational partner for the NIA AMP-AD and MODEL-AD initiatives. By design, this will provide drug discovery capability to bridge the foundational work in target discovery (AMP-AD) with newly discovered lead molecules characterized in AD animal models based on human pathology, genetics and translational biomarkers (MODEL-AD). To accomplish the mission of the ADDD CENTER, we have assembled a world-class team of scientists and capabilities from Indiana University, Purdue University, and the Indiana Clinical and Translational Sciences Institute (CTSI). This team has considerable expertise in Alzheimer’s disease biology, CNS pharmaceutical drug discovery and development, and scientific excellence in the core discovery technologies that will drive the ADDD CENTER’s contributions and deliverables. A key advantage and differentiated strength of the proposed ADDD CENTER is the primary scientific coordination and administration through the Indiana University School of Medicine. Specifically, this concentrates a strong and long-standing commitment to neurodegenerative research through co-presence with the NIA-supported Indiana Alzheimer’s Disease Center under the direction of Dr. Andy Saykin, the MODEL-AD consortium under the direction of Dr. Bruce Lamb, and the Longitudinal Early Onset Alzheimer’s Disease (LEAD) study under the direction of Dr. Liana Apostolova. The Specific Aims of the ADDD CENTER are: 1. Create a dynamic portfolio of well-characterized AD drug discovery targets representing novel intervention hypotheses that capitalize on significant investments in basic research and emerging disease understanding. 2. Perform advanced pre-clinical target validation and enablement studies to prioritize the best opportunities for therapeutic discovery. 3. Create high-quality and well-characterized lead molecules for prioritized targets that meet rigorous milestone criteria and are valued opportunities for further translational investment. 4. Create a robust and flexible data sharing platform to enable global researchers with data and target enablement packages to expand on the work of the ADDD CENTER.

印第安纳州大学医学院阿尔茨海默病药物发现（ADDD）中心的战略目标是整合早期药物发现的复杂能力，并为新兴阿尔茨海默病（AD）靶向假说（超越Ab）的更广泛研究做出贡献，目标是产生新类别的潜在治疗方法。具体而言，ADDD中心将成为NIA AMP-AD和MODEL-AD倡议的战略和运营合作伙伴。通过设计，这将提供药物发现能力，将靶点发现（AMP-AD）的基础工作与基于人类病理学、遗传学和翻译生物标志物（MODEL-AD）的AD动物模型中新发现的先导分子联系起来。为了完成ADDD中心的使命，我们组建了一个世界级的科学家团队，他们来自印第安纳州大学、普渡大学和印第安纳州临床和转化科学研究所（CTSI）。该团队在阿尔茨海默病生物学，CNS药物发现和开发方面拥有相当丰富的专业知识，并在核心发现技术方面具有卓越的科学成就，这将推动ADDD中心的贡献和交付成果。拟议的ADDD中心的一个关键优势和差异化优势是通过印第安纳州大学医学院进行主要的科学协调和管理。具体来说，这集中了一个强大的和长期的承诺，通过共同存在与美国国立情报局支持的印第安纳州阿尔茨海默病中心的指导下，博士安迪Saykin，模型-AD财团的指导下，博士布鲁斯兰姆，纵向早发性阿尔茨海默病（LEAD）的研究下，博士利亚纳Apostolova的方向。ADDD中心的具体目标是：1。创建一个动态的组合，充分表征AD药物发现目标，代表新的干预假设，利用基础研究和新兴疾病理解的重大投资。2.执行先进的临床前目标验证和启用研究，以优先考虑治疗发现的最佳机会。3.为符合严格里程碑标准的优先目标创建高质量和良好表征的先导分子，并为进一步转化投资提供宝贵机会。4.创建一个强大而灵活的数据共享平台，使全球研究人员能够使用数据和目标支持包扩展ADDD中心的工作。